Candid Therapeutics brings to UCB two clinical-stage T cell engagers in development for autoimmune disorders. To accept UCB’s offer, Candid terminated its reverse merger with Rallybio.
The post UCB Joins the Chase for Immune System Reset With $2B Acquisition appeared first on MedCity News.
